[Acute hearing loss in children with preliminary irradiation of intracranial tumors following a single high-dose cisplatin administration].
Cis-platinum either alone (120 mg/m2) or in combination (100 mg/m2) with ifosfamide (3 g/m2) was administered to two children with brain tumors 14 weeks and 3 months respectively following cranial radiation. Both children developed acute bilateral deafness. The role of capillary hyperemia following radiation for the pathogenesis of this severe complication is discussed. Fractionated administration of cis-platinum (e.g. 20 mg/m2/day X 5 days) may be less ototoxic.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy; D002648:Child; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects*; D003131:Combined Modality Therapy; D003638:Deafness / Q000139:chemically induced*; D004305:Dose-Response Relationship, Drug; D007758:Ear, Inner / Q000528:radiation effects*; D005260:Female; D005910:Glioma / Q000188:drug therapy; D003639:Hearing Loss, Sudden / Q000139:chemically induced; D006801:Humans; D007263:Infusions, Parenteral; D008297:Male; D010870:Pineal Gland; D011832:Radiation Injuries / Q000209:etiology*; D013724:Teratoma / Q000188:drug therapy
D002945:Cisplatin
Akuter Hörverlust bei Kindern mit vorbestrahlten intrakraniellen Tumoren nach einmaliger hochdosierter Cis-Platinum-Gabe.